At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 108 enrolled
Drug / intervention
NVA237 +1 moredrug
Likely dose
NVA237 50 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD
In Brief
A Phase 3 clinical trial evaluating NVA237 and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 108 participants across 10 sites in 5 countries.
Detailed Summary
The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesGermany, Italy, Romania, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionFeb 2011
TodayJul 2026
First PostedJun 30, 2010
Enrollment StartJun 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.0 years ago
Interventions
NVA237drug
50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Placebodrug
Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily